German Accelerator Life Sciences

Page Header Image

InGeneron Establishes Presence in Cambridge, MA and Initiates Collaboration with German Accelerator Life Sciences


Cambridge, MA, USA and Berlin, Germany, December 5, 2016 – InGeneron, a regenerative medicine and biotechnology company, today announced its acceptance to the German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi). As part of the GALS program, InGeneron has established an additional US presence in Cambridge, MA.

“Our new presence in Cambridge will help us access one of the world’s leading life sciences and biotechnology hubs and tap into the local talent pool,” said Michael Coleman, Ph.D., Chief Executive Officer of InGeneron. “Additionally, being accepted into the GALS program is a commendation for our teams on both sides of the Atlantic. The broad network and expertise of GALS represents a significant opportunity for the company.”

“We are excited to start our collaboration with InGeneron. The company’s adipose-derived regenerative cell-based technology has great potential across several indications. We are confident that GALS can add significant value and help InGeneron establish its innovative approach in the US and Europe,” commented Christoph Lengauer, Ph.D., MBA, CEO of the German Accelerator Life Sciences.

GALS will provide InGeneron with a team of mentors and leverage its industry network to support the company’s US activities and development in Europe. GALS’ mentorship will support InGeneron as the company continues to execute on its plans for clinical development in the US, expanding its distribution network, further developing its reimbursement strategies in the US and Europe, and broadening its investor base.


About InGeneron

InGeneron is elevating the field of regenerative medicine by translating robust science into proven patient benefit. Our purpose is to set new therapeutic standards by enabling physicians to use the patients’ own regenerative cells at point of care. With the initial focus on key orthopedic and wound healing indications, we will make regenerative cell therapies broadly accessible across multiple medical fields.


About the German Accelerator Life Sciences

The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi), with the goal of helping German startups and young companies succeed in the global marketplace. GALS offers support in multiple areas, from free office space in the world’s leading life science innovation hub, to mentoring and advising from industry experts and experienced leaders. GALS opened its doors in October 2015 and has its headquarters in Cambridge, Massachusetts.



Ron Stubbers
President & VP of Operations
+1 713 440 9900
[email protected]